Hepcidin in chronic kidney disease: not an anaemia management tool, but promising as a cardiovascular biomarker

被引：1

作者：

van der Weerd, N. C. ^{[1
]}

Grooteman, M. P. C. ^{[2
]}

Nube, M. J. ^{[2
]}

ter Wee, P. M. ^{[2
]}

Swinkels, D. W. ^{[3
]}

Gaillard, C. A. J. M. ^{[4
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Nephrol, NL-1105 AZ Amsterdam, Netherlands

[2] Vrije Univ Amsterdam, Med Ctr, Dept Nephrol, Amsterdam, Netherlands

[3] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Lab Genet Endocrine & Metab Dis, NL-6525 ED Nijmegen, Netherlands

[4] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands

来源：

NETHERLANDS JOURNAL OF MEDICINE | 2015年 / 73卷 / 03期

关键词：

Anaemia; cardiovascular; chronic kidney disease; dialysis; hepcidin; iron; CHRONIC-HEMODIALYSIS PATIENTS; ERYTHROPOIESIS-STIMULATING AGENTS; FOAM CELL-FORMATION; SERUM HEPCIDIN; IRON-METABOLISM; MASS-SPECTROMETRY; INTRAINDIVIDUAL VARIABILITY; MAINTENANCE HEMODIALYSIS; ATHEROSCLEROTIC PLAQUE; ARTERIAL STIFFNESS;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hepcidin is a key regulator of iron homeostasis and plays a role in the pathogenesis of anaemia of chronic disease. Its levels are increased in patients with chronic kidney disease (CKD) due to diminished renal clearance and an inflammatory state. Increased hepcidin levels in CKD patients are supposed to be responsible for functional iron deficiency in these patients and contribute to renal anaemia and resistance to erythropoiesis-stimulating agents. Therefore, hepcidin was purported to be useful as a management tool guiding treatment of renal anaemia. Furthermore, since hepcidin is associated with iron accumulation in macrophages in the vessel wall inducing oxidative stress and atherosclerosis, it has been speculated that hepcidin might function as a biomarker of cardiovascular disease. In this descriptive review, the merits of hepcidin with respect to its role in the pathophysiology of renal anaemia in CKD patients, its presumptive role as a practical diagnostic tool guiding management of renal anaemia, and its possible usefulness as a prognostic biomarker will be discussed.

引用

页码：108 / 118

页数：11

共 94 条

[81] Hepcidin levels in chronic hemodialysis patients: a critical evaluation [J].

Valenti, Luca ;

Messa, Piergiorgio ;

Pelusi, Serena ;

Campostrini, Natascia ;

Girelli, Domenico .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2014, 52 (05) :613-619

[82] Serum Hepcidin and Macrophage Iron Correlate With MCP-1 Release and Vascular Damage in Patients With Metabolic Syndrome Alterations [J].

Valenti, Luca ;

Dongiovanni, Paola ;

Motta, Benedetta Maria ;

Swinkels, Dorine W. ;

Bonara, Paola ;

Rametta, Raffaela ;

Burdick, Larry ;

Frugoni, Cecelia ;

Fracanzani, Anna Ludovica ;

Fargion, Silvia .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (03) :683-690

[83] HFE Mutations Modulate the Effect of Iron on Serum Hepcidin-25 in Chronic Hemodialysis Patients [J].

Valenti, Luca ;

Girelli, Domenico ;

Valenti, Giovanni Francesco ;

Castagna, Annalisa ;

Como, Giovanna ;

Campostrini, Natascia ;

Rametta, Raffaela ;

Dongiovanni, Paola ;

Messa, Piergiorgio ;

Fargion, Silvia .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (08) :1331-1337

[84] Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients [J].

van der Putten, Karien ;

Jie, Kim E. ;

van den Broek, Daan ;

Kraaijenhagen, Rob J. ;

Laarakkers, Coby ;

Swinkels, Dorine W. ;

Braam, Branko ;

Gaillard, Carlo A. .

EUROPEAN JOURNAL OF HEART FAILURE, 2010, 12 (09) :943-950

[85] Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients [J].

van der Weerd, Neelke C. ;

Grooteman, Muriel P. C. ;

Bots, Michiel L. ;

van den Dorpel, Marinus A. ;

den Hoedt, Claire H. ;

Mazairac, Albert H. A. ;

Nube, Menso J. ;

Penne, E. Lars ;

Wetzels, Jack F. M. ;

Wiegerinck, Erwin T. ;

Swinkels, Dorine W. ;

Blankestijn, Peter J. ;

ter Wee, Piet M. .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 (12) :3062-3071

[86] Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents [J].

van der Weerd, Neelke C. ;

Grooteman, Muriel P. C. ;

Bots, Michiel L. ;

van den Dorpel, Marinus A. ;

den Hoedt, Claire H. ;

Mazairac, Albert H. A. ;

Nube, Menso J. ;

Penne, E. Lars ;

Gaillard, Carlo A. ;

Wetzels, Jack F. M. ;

Wiegerinck, Erwin T. ;

Swinkels, Dorine W. ;

Blankestijn, Peter J. ;

ter Wee, Piet M. .

PLOS ONE, 2012, 7 (07)

[87] Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans [J].

van Eijk, Lucas T. ;

John, Aaron S. E. ;

Schwoebel, Frank ;

Summo, Luciana ;

Vauleon, Stephanie ;

Zoellner, Stefan ;

Laarakkers, Coby M. ;

Kox, Matthijs ;

van der Hoeven, Johannes G. ;

Swinkels, Dorine W. ;

Riecke, Kai ;

Pickkers, Peter .

BLOOD, 2014, 124 (17) :2643-2646

[88] Medical progress: Anemia of chronic disease [J].

Weiss, G ;

Goodnough, LT .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :1011-1023

[89] Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy [J].

Weiss, G. ;

Theurl, I. ;

Eder, S. ;

Koppelstaetter, C. ;

Kurz, K. ;

Sonnweber, T. ;

Kobold, U. ;

Mayer, G. .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (10) :883-890

[90] Assessing iron status: Beyond serum ferritin and transferrin saturation [J].

Wish, Jay B. .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 :S4-S8

← 1 2 3 4 5 6 7 8 9 10 →